Please use this identifier to cite or link to this item:
Title: Effect of subcutaneous high-dose methotrexate treatment on the management of rheumatoid arthritis
Authors: Tufan, Müge Aydın
Ersözlü, Emine Duygu
Köseoğlu, Hamide Kart
Yücel, Ahmet Eftal
Keywords: Drug administration routes
rheumatoid arthritis
Issue Date: 2021
Publisher: Cukurova Univ, Fac Medicine
Abstract: Purpose: Methotrexate (MTX) is still the main treatment option for rheumatoid arthritis (RA). There is no consensus on drug administration routes and dosage when administered alone or in combination with other drugs. This study aims to identify the effects of early administration of a combination therapy containing high dose subcutaneous (SC) MTX on RA management. Materials and Methods: Forty-five patients with RA who newly diagnosed were divided into two groups randomly. The patients who took 12.5 mg SC MTX per week in the first 4 weeks defined as a low dose group. The patients who took 25 mg SC MTX per week in the first 4 weeks defined as a high dose group. Then, patients of both groups continued with 12.5 mg oral MTX per week. Clinical and laboratory findings, disease activity scores and response rates of the patients were recorded at the beginning, 3rd months and 6th months. Results: There was no significant difference between the two groups at 3rd month's values. There were statistically significant improvements at 6th month's values. Values were as follows in low and high dose groups: mean DAS28-CRP (3.5 vs 2.7), VAS pain score (3.3 vs 1.6), and TJC28 (3 vs 1.5), respectively. Conclusion: Early administration of high-dose SC MTX effectively controls disease activity and increases the quality of life in RA patients.
ISSN: 2602-3032
Appears in Collections:Dahili Tıp Bilimleri Bölümü / Department of Internal Medical Sciences
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record

CORE Recommender

Page view(s)

checked on Mar 20, 2023

Google ScholarTM



Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.